Pure Global
NCT06419608

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder
Biohaven Therapeutics Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Major Depressive Disorder
Drug/Device/Intervention
BHV-7000
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Biohaven Therapeutics Ltd.
Funder
Biohaven Pharmaceuticals, Inc.
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jul 01, 2025
Enrollment
300 participants
Primary outcome

Change in Montgomery- Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6

Summary

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants
 with Major Depressive Disorder (MDD)

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419608
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419608 through Pure Global AI's free database. This Phase 2 trial is sponsored by Biohaven Therapeutics Ltd. and is currently Not yet recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.